VTRS

Paul Campbell

Known title: See RemarksCIK: 0001657568

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal. Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.

this person other insiders at VTRS

Transaction History

VTRS▼ Sell$810K
VTRS▼ Sell$284K
VTRS▲ Buy$0
VTRS▼ Sell$171K
VTRS▲ Buy$0
VTRS▼ Sell$9K
VTRS▲ Buy$0
VTRS▼ Sell$110K
VTRS▲ Buy$0
VTRS▼ Sell$10K
VTRS▼ Sell$117K
VTRS▲ Buy$0
VTRS▼ Sell$17K
VTRS▲ Buy$0
VTRS▼ Sell$1.1M
VTRS▲ Buy$0
VTRS▲ Buy$0
VTRS▲ Buy$0
VTRS▼ Sell$73K
VTRS▲ Buy$0
VTRS▼ Sell$10K
VTRS▲ Buy$0
VTRS▼ Sell$70K
VTRS▲ Buy$0
VTRS▼ Sell$3K
VTRS▼ Sell$694K
VTRS▲ Buy$0
VTRS▼ Sell$74K
VTRS▲ Buy$0
VTRS▼ Sell$7K
VTRS▼ Sell$347K
VTRS▼ Sell$300K
VTRS▲ Buy$0
VTRS▲ Buy$0
VTRS▼ Sell$8K
VTRS▼ Sell$97K
VTRS▼ Sell$98K
VTRS▲ Buy$0
VTRS▲ Buy$0
VTRS▼ Sell$5K
VTRS▼ Sell$77K
VTRS▼ Sell$10K
VTRS▼ Sell$410K
VTRS▲ Buy$0
VTRS▲ Buy$0
VTRS▲ Buy$0
VTRS▲ Buy$0
VTRS▼ Sell$87K
VTRS▼ Sell$3K
VTRS▲ Buy$0
VTRS▲ Buy$0
VTRS▼ Sell$5K
VTRS▲ Buy$0
VTRS▲ Buy$0
VTRS▼ Sell$37K
VTRS▼ Sell$125K
VTRS▲ Buy$0
VTRS▼ Sell$68K
VTRS▲ Buy$0
VTRS▼ Sell$3K
VTRS▲ Buy$0
VTRS▼ Sell$64K
VTRS▲ Buy$0
VTRS▼ Sell$21K
VTRS▲ Buy$0
VTRS▼ Sell$1K
VTRS▲ Buy$0
VTRS▼ Sell$71K
VTRS▲ Buy$0
VTRS▼ Sell$2K
VTRS▲ Buy$0
VTRS▼ Sell$31K
VTRS▲ Buy$0
VTRS▼ Sell$2K
VTRS▲ Buy$0
VTRS▼ Sell$2K
VTRS▲ Buy$0
VTRS▼ Sell$84
VTRS▼ Sell$0
VTRS▼ Sell$0

We use analytics to understand how market-wall is used. No personal data is sold.